ClearPoint Neuro Reports 36% Revenue Growth in Q3 2026 Driven by IRRAflow Integration
ClearPoint Neuro (CLPT) delivered strong third-quarter results for fiscal year 2026, reporting total revenue of $12.1 million, a 36% increase year-over-year. This growth was primarily fueled by the integration of the IRRAflow portfolio and significant expansion in neurosurgery navigation and therapy revenue, which rose 59%. The company also achieved record capital equipment and software revenue, reaching $1.7 million. Despite the top-line strength, gross margins compressed to 58% from 63% due to overhead at the new ClearPoint Advanced Laboratories (CAL) facility and amortization of acquired intangibles. However, management demonstrated improved scalability as revenue growth outpaced operating expense growth. The company updated its 2026 annual revenue guidance to a range of $48 million to $50 million, supported by realized synergies from recent acquisitions.
Tickers: $CLPT
Topics: Acquisition Integration Clinical Trials Financial Guidance Revenue Growth
Read the full article at Motley Fool
Part of the story Freedom Financial Holdings Reports Q3 2026 Earnings Growth and Increases Share Repurchase Authorization (27 articles)